Alpine Immune Sciences, Inc.
ALPN
Price:
$64.97
Market Cap:
$4.46B
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with Ab...[Read more]
Industry
Biotechnology
IPO Date
2015-06-17
Stock Exchange
NASDAQ
Ticker
ALPN
PE Ratio
[-101.52]
ROE
[-14.86%]
Current Ratio
[9.56]
Dividend Yield
[0%]
Enterprise Value
[4.43B]
Dividend History
The ROE as of November 2024 (TTM) for Alpine Immune Sciences, Inc. (ALPN) is -14.86%
According to Alpine Immune Sciences, Inc.’s latest financial reports and current stock price. The company's current ROE is -14.86%. This represents a change of 219.75% compared to the average of -4.65% of the last 4 quarters.
Alpine Immune Sciences, Inc. (ALPN) Historical ROE (quarterly & annually)
How has ALPN ROE performed in the past?
The mean historical ROE of Alpine Immune Sciences, Inc. over the last ten years is -35.32%. The current -14.86% ROE has changed -57.93% with respect to the historical average. Over the past ten years (40 quarters), ALPN's ROE was at its highest in in the December 2014 quarter at 22.13%. The ROE was at its lowest in in the June 2020 quarter at -61.18%.
Average
-35.32%
Median
-36.91%
Minimum
-144.31%
Maximum
95.45%
Alpine Immune Sciences, Inc. (ALPN) ROE by Quarter and Year
Discovering the peaks and valleys of Alpine Immune Sciences, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 729.69%
Maximum Annual ROE = 95.45%
Minimum Annual Increase = -128.63%
Minimum Annual ROE = -144.31%
| Year | ROE | Change |
|---|---|---|
| 2023 | -9.81% | -69.52% |
| 2022 | -32.19% | -22.67% |
| 2021 | -41.63% | -7.38% |
| 2020 | -44.95% | -68.85% |
| 2019 | -144.31% | 76.36% |
| 2018 | -81.83% | 729.69% |
| 2017 | -9.86% | -82.62% |
| 2016 | -56.76% | 107.67% |
| 2015 | -27.33% | -128.63% |
| 2014 | 95.45% | 437.95% |
Alpine Immune Sciences, Inc. (ALPN) Average ROE
How has ALPN ROE performed in the past?
The current ROE of Alpine Immune Sciences, Inc. (ALPN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-27.88%
5-year avg
-54.58%
10-year avg
-35.32%
Alpine Immune Sciences, Inc. (ALPN) ROE vs. Peers
How is ALPN’s ROE compared to its peers?
Alpine Immune Sciences, Inc.’s ROE is less than Terns Pharmaceuticals, Inc. (0%), greater than Day One Biopharmaceuticals, Inc. (-32.76%), greater than Acumen Pharmaceuticals, Inc. (-22.40%), greater than Amylyx Pharmaceuticals, Inc. (-32.99%), greater than MoonLake Immunotherapeutics (-85.39%), greater than Anebulo Pharmaceuticals, Inc. (-15.89%), greater than Adagene Inc. (-184.40%), greater than Acrivon Therapeutics, Inc. Common Stock (-50.10%), greater than AnaptysBio, Inc. (-47.95%), greater than Mineralys Therapeutics, Inc. (-287.94%), greater than Tenaya Therapeutics, Inc. (-55.92%), greater than Bicycle Therapeutics plc (-86.16%), greater than IGM Biosciences, Inc. (-27.35%), greater than Monte Rosa Therapeutics, Inc. (-155.42%), greater than Stoke Therapeutics, Inc. (-62.68%), greater than null (-54.45%),
| Company | ROE | Market cap |
|---|---|---|
| 0% | $491.80M | |
| -32.76% | $1.38B | |
| -22.40% | $142.39M | |
| -32.99% | $361.25M | |
| -85.39% | $3.43B | |
| -15.89% | $37.86M | |
| -184.40% | $97.11M | |
| -50.10% | $202.87M | |
| -47.95% | $677.65M | |
| -287.94% | $621.09M | |
| -55.92% | $188.54M | |
| -86.16% | $1.42B | |
| -27.35% | $528.64M | |
| -155.42% | $521.60M | |
| -62.68% | $605.41M | |
| -54.45% | $0 |
Build a custom stock screener for Alpine Immune Sciences, Inc. (ALPN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Alpine Immune Sciences, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Alpine Immune Sciences, Inc. (ALPN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Alpine Immune Sciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Alpine Immune Sciences, Inc.'s ROE?
How is the ROE calculated for Alpine Immune Sciences, Inc. (ALPN)?
What is the highest ROE for Alpine Immune Sciences, Inc. (ALPN)?
What is the 3-year average ROE for Alpine Immune Sciences, Inc. (ALPN)?
What is the 5-year average ROE for Alpine Immune Sciences, Inc. (ALPN)?
How does the current ROE for Alpine Immune Sciences, Inc. (ALPN) compare to its historical average?